Moroccan pharmaceutical group Laprophan has strengthened its industrial presence in the pharmaceutical sector through its subsidiary Amanys Pharma, which was fully acquired in 2024. The company is preparing to launch a new unit specialized in the manufacture of sterile injectable medications. This new facility, located in Aïn El Aouda, was presented during a press visit organized following the announcement of the group's planned stock market introduction.
The new unit, built on an area of 18,000 square meters, represents an investment of 374 million dirhams ($374 million). It is intended for the manufacture of injectable medications packaged in bottles and flexible pouches. The production capacity is expected to reach approximately 30 million units per year, while its logistics installations will allow for the storage of 7,000 pallets. The site is part of an industrial complex located on a 62,000 square meter plot.
The unit was designed according to European good manufacturing practices (EU-GMP) and integrates highly automated equipment and devices to prevent contamination risks. According to Mohammed Squalli Houssaini, Deputy Managing Director and responsible pharmacist at Amanys Pharma, the facility features a completely closed system to avoid contamination. The installations meet European and American requirements for the manufacture of sterile products.
The design and construction of the unit took nearly four years, and the equipment is now ready for industrial use, with a planned start-up in 2027. The new unit aims primarily to meet the needs of the national pharmaceutical market while offering export possibilities to African and European markets. Integrated quality control laboratories will allow for verifying medication compliance and controlling the different manufacturing stages.
According to Moulay Younous Elalamy, an administrator at Amanys Pharma, this installation will initially be dedicated to large-volume injectables, before possible expansion to small-volume injectables. The Aïn El Aouda complex also includes a unit specialized in beta-lactam antibiotics in solid oral forms, with a current capacity of 15 million units per year, expected to reach 25 million by 2027.
This investment in injectables is part of Laprophan's development strategy, particularly since the acquisition of 100% of Amanys Pharma in 2024. Amanys Pharma specializes in the manufacture, importation, distribution, and export of medications, with activities in antibiotics, intensive care, hematology, and specialized oncology.
The expansion takes place in the context of Laprophan's planned stock market introduction. The group aims to strengthen its position in the pharmaceutical sector, both locally and internationally. With this new unit, Laprophan is poised to increase its production capacity and diversify its product offerings, solidifying its presence in the market.
Key points
- Laprophan invests $374 million in a new sterile injectable unit in Morocco.
- The unit will have a capacity of 30 million units per year and will meet European and American requirements for sterile product manufacturing.
- The new unit is part of Laprophan's development strategy, particularly since the acquisition of Amanys Pharma in 2024.